Niosome are non-ionic surfactant vesicles obtained by hydrating mixture of cholesterol and nonionic surfactants. It can be used as carriers of amphiphilic and lipophilic drug. In niosomes drug delivery system, the medication is encapsulated in a vesicle. Niosomes are biodegradable, biocompatible non-immunogenic and exhibit flexibility in their structural characterization. The main object of this review the application of niosome technology is used to treat a number of diseases, niosome have good opportunity in research and beneficial for researcher and pharma industries. Niosome appears to be a well preferred drug delivery system over liposome as niosome being stable and economic. Also niosomes have great drug delivery potential for targeted delivery of anti-cancer, anti-infective agents. Drug delivery potential of niosome can enhances by using novel drug delivery concepts like proniosomes, discomes and aspasome. Niosomes also serve better aid in diagnostic imaging and as a vaccine adjuvant. Thus these areas need further exploration and research so as to bring out or to make for commercially available niosomal preparation.
INTRODUCTION
Paul Ehrlich, in 1909, initiated the era of development for targeted delivery when he envisaged a drug delivery mechanism that would target directly to diseased cell. Drug targeting can be defined as the ability to direct a therapeutic agent specifically to desired site of action with little or no interaction with non target tissue. In niosomes drug delivery system the medication is encapsulated in a vesicle. (Baillie et al., 1985) The vesicle is composed of a bilayer of non-ionic surface active agents and hence the name niosomes. In niosomes, the vesicles forming amphiphilic is a non-ionic surfactant such as Span -60 which is usually stabilized by addition of cholesterol and small amount of anionic surfactant such as dicetyl phosphate. (Hunter et al., 1988) Vol. 6, Issue 3 | magazine.pharmatutor.org
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STRUCTURE OF NIOSOME (GAYATRI ET AL., 2000)
A typical niosome vesicle would consist of a vesicle forming amphiphilic i.e. a non-ionic surfactant such as Span-60, which is usually stabilized by the addition of cholesterol and a small amount of anionic surfactant such as dicetyl phosphate, which also helps in stabilizing the vesicle.
Compositions of niosomes: (Gayatri et al., 2000)
The two major components used for the preparation of niosomes are, 1. Cholesterol 2. Nonionic surfactants
Cholesterol
Cholesterol is a steroid derivative, which is used to provide rigidity and proper shape, conformation to the niosomes preparations.
Nonionic surfactants
The following non-ionic surfactants are generally used for the preparation of niosomes. The non ionic surfactants possess a hydrophilic head and a hydrophobic tail.
PREPARATION METHODS OF NIOSOMES Ether injection method
The ether injection method is essentially based on slowly introducing a solution of surfactant dissolved in diethyl ether into warm water maintained at 60°C. The surfactant mixture in ether is injected through 14-gauge needle into an aqueous solution of material. Vaporization of ether leads to formation of single layered vesicles. The particle size of the niosomes formed depend on the conditions used the diameter of the vesicle range from 50 to 1000 nm.
Hand shaking method (thin film hydration technique): (Khandare et al., 1994) In this method the surfactant and cholesterol are dissolved in a volatile organic solvent (such as diethyl either, chloroform or methanol) in a round bottom flask. The organic solvent is removed at room temperature (20°C) using rotary evaporator leaving a thin layer of solid mixture deposited on the wall of the flask. The dried surfactant film can be rehydrated with aqueous phase at 0-60°C with gentle agitation to yield multilamellar niosomes.
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Sonication Method
In this method an aliquot of drug solution in buffer is added to the surfactant/cholesterol mixture in a 10-ml glass vial. The mixture is probe sonicated at 60°C for 3 minutes using a sonicator with a titanium probe to yield niosomes. (Rogerson et al., 1988) Micro fluidization is a recent technique used to prepare unilamellar vesicles of defined size distribution. This method is based on submerged jet principle in which two fluidized streams interact at ultra high velocities, in precisely defined micro channels within the interaction chamber. The impingement of thin liquid sheet along a common front is arranged such that the energy supplied to the system remains within the area of niosomes formation. The result is a greater uniformity, smaller size and better reproducibility of niosomes formed. The Bubble Method (Ijeoma et al., 1998) The bubbling unit consists of round-bottomed flask with three necks, and this is positioned in a water bath to control the temperature. Water-cooled reflux and thermometer is positioned in the first and second neck and nitrogen supply through the third neck. Cholesterol and surfactant are dispersed together in this buffer (PH 7.4) at 70°C, the dispersion mixed for 15 seconds with high shear homogenizer and immediately afterwards "bubbled" at 70°C using nitrogen gas to yield niosomes. release rate of encapsulated material and therefore an increase of the rigidity of the bilayers obtained. Presence of charge tends to increase the interlamellar distance between successive bilayers in multilamellar vesicle structure and leads to greater overall entrapped volume.
Micro fluidization method
Multiple membrane extrusion method
Resistance to osmotic stress
The diameter is reduced by addition of hypertonic salt solution to suspension of niosomes.
Temperature of Hydration
Hydration temperature influences the shape and size of niosome.
CHARACTERIZATION OF NIOSOMES (HU ET AL., 1994)
Measurement of Angle of repose
The angle of repose of dry niosomes powder was measured by a funnel method. The niosomes powder was poured into a funnel which was fixed at a position so that the 13mm outlet orifice of the funnel is 5cm above a level black surface. The powder flows down from the funnel to form a cone on the surface and the angle of repose was then calculated by measuring the height of the cone and the diameter of its base.
Scanning electron microscopy (Sternberg., 1998) Particle size of niosomes is very important characteristic. The surface morphology (roundness, smoothness, and formation aggregates) and the size distribution of niosomes were studied by Scanning Electron Microscopy (SEM). Niosomes were sprinkled on to the double-sided tape that was affixed on aluminum stubs. The aluminum stub was placed in the vacuum chamber of a scanning electron microscope (XL 30 ESEM with EDAX, Philips, Netherlands). The samples were observed for morphological characterization using a gaseous secondary electron detector (working pressure: 0.8 torr, acceleration voltage: 30.00 KV) XL 30, (Philips, Netherlands).
Optical Microscopy
The niosomes were mounted on glass slides and viewed under a microscope (Medilux-207RII, KyowaGetner, Ambala, India) with a magnification of 1200X for morphological observation after suitable dilution.
The photomicrograph of the preparation also obtained from the microscope by using a digital SLR camera. (Sternberg., 1998) The vesicle dispersions were diluted about 100 times in the same medium used for their preparation. Vesicle size was measured on a particle size analyzer (Laser diffraction particle size analyzer, Sympatec, Germany). The apparatus consists of a He-Ne laser beam of 632.8 nm focused with a minimum power of 5 mW using a Fourier lens [R-5] to a point at the center of multielement detector and a small volume sample holding cell (Su cell). The sample was stirred using a stirrer before determining the vesicle size. Hu C. and Rhodes 7 in 1999 reported that the average particle size of niosomes derived niosomes is approximately 6µm while that of conventional niosomes is about 14µm.
Measurement of vesicle size
Entrapment efficiency (Sternberg., 1998) Entrapment efficiency of the niosomal dispersion in can be done by separating the unentrapped drug by dialysis centrifugation or gel filtration as described above and the drug remained entrapped in niosomes is determined by complete vesicle disruption using 50% n-propanol or 0.1% Triton X-100 and analyzing the resultant solution by appropriate assay method for the drug. Where, Osmotic shock (Sternberg., 1998) The change in the vesicle size can be determined by osmotic studies. Niosomes formulations are incubated with hypotonic, isotonic, hypertonic solutions for 3 hours. Then thechanges in the size of vesicles in the formulations are viewed under optical microscopy.
Stability studies(Theresa., 1988) To determine the stability of niosomes, the optimized batch was stored in airtight sealed vials at different temperatures. Surface characteristics and percentage drug retained in niosomes and niosomes derived from proniosomes were selected as parameters for evaluation of the stability, since instability of the formulation would reflect in drug leakage and a decrease. In the percentage drug retained. The niosomes were sample at regular intervals of time (0,1,2,and 3months ),observed for Niosomes.  It is used in ophthalmic drug delivery.  Niosomal system can be used as diagnostic agents.
Immunological application of niosomes (Navneet et al., 2014) Niosomes have been used for studying the nature of the immune response provoked by antigens. Niosomes can also be utilized for targeting drugs to organs other than the Reticulo-Endothelial System. A carrier system (such as antibodies) can be attached to niosomes (as immunoglobulin's bind readily to the lipid surface of the niosome) to target them to specific organs.
Sustained Release (Navneet et al., 2014) Sustained release action of niosomes can be applied to drugs which have low therapeutic index and have low solubility with water since those could be maintained in the circulation via niosomal encapsulation.
Localized Drug Action (Navneet et al., 2014) Drug delivery through niosomes is one of the approaches to achieve localized drug action, since their size and low penetrability through epithelium and connective tissue keeps the drug localized at the site of administration.
Niosomes as Drug Carriers (Navneet et al., 2014)
Niosomes have also been used as carriers for iobitridol, a diagnostic agent used for X-ray imaging. Topical niosomes may serve as solubilization matrix, as a local depot for sustained release of dermally active compounds, as penetration enhancers, or as rate-limiting membrane barrier for the modulation of systemic absorption of drugs.
Transdermal delivery of drugs by niosomes (Navneet et al., 2014)
Those drug have slow penetration of medicament through skin is the major drawback of transdermal route of delivery. An increase in the penetration rate has been achieved by transdermal delivery of drug incorporated in niosomes. From the above discussed studies, and confocal microscopy, it was seen that non-ionic vesicles could be formulated to target pilosebaceous glands. Topical niosomes may serve as solubilization matrix, as a local depot for sustained release of dermally active compounds, as penetration enhancers, or as rate-limiting membrane barrier for the modulation of systemic absorption of drugs.
Leishmaniasis (Navneet et al., 2014) Leishmaniasis is a disease in which a parasite of the genus Leishmania invades the cells of the liver and spleen. Use of niosomes in tests conducted showed that it was possible to administer higher levels of the drug without the triggering of the side effects, and thus allowed greater efficacy in treatment.
Delivery of Peptide Drugs (Navneet et al., 2014) Oral peptide drug delivery has long been faced with a challenge of bypassing the enzymes which would breakdown the peptide. Use of niosomes to successfully protect the peptides from gastrointestinal peptide breakdown is being investigated. In an in vitro study conducted by oral delivery of a vasopressin derivative entrapped in niosomes showed that entrapment of the drug significantly increased the stability of the peptide.
Niosome formulation as a brain targeted delivery system for the vasoactive intestinal peptide
Radiolabelled (I125) VIP-loaded glucosebearing niosomes were injected intravenously to mice. Encapsulated VIP within glucosebearing niosomes exhibits higher VIP brain uptake as compared to control. (Navneet et al., 2014) Niosomes can be used as a carrier for hemoglobin. Niosomal suspension shows a visible spectrum superimposable which is likely to be or, onto that of free hemoglobin. Vesicles are permeable to oxygen and hemoglobin dissociation curve can be modified similarly to non-encapsulated hemoglobin. Antineoplastic Treatment Most antineoplastic drugs cause severe side effects. Niosomes can alter the metabolism; prolong circulation and half life of the drug, thus decreasing the side effects of the drugs. Niosomes are decreased rate of proliferation of tumor and higher plasma levels accompanied by slower elimination.
Niosomes as carriers for Hemoglobin
Drug Targeting (Navneet et al., 2014) One of the most useful aspects of niosomes is their ability to target drugs. Niosomes can be used to target drugs to the reticuloendothelial system. The reticulo-endothelial system (RES) preferentially takes up niosome vesicles. The uptake of niosomes is controlled by circulating serum factors called opsonins. These opsonins mark the niosome for clearance. Such localization of drugs is utilized to treat tumors in animals known to metastasize to the liver and spleen. This localization of drugs can also be used for treating parasitic infections of the liver. Niosomes can also be utilized for targeting drugs to organs other than the RES. A carrier system (such as antibodies) can be attached to niosomes (as immunoglobulin's bind readily to the lipid surface of the niosome) to target them to specific organs. 
ROUTE OF APPLICATION OF NIOSOMES DRUGS
CONCLUSION
Niosomal drug delivery system is one of the best examples of great evolution in drug delivery technologies and nanotechnology. It is obvious that niosome appears to be a well preferred drug delivery system over other dosage form as niosome mostly stable in nature and economic. There is lot of scope to encapsulate toxic anti-cancer drugs, anti-infective drugs, anti-AIDS drugs, anti-inflammatory drugs, anti-viral drugs, etc. in niosomes and to use them as promising drug carriers to achieve better bioavailability and targeting properties and for reducing the toxicity and side effects of the drugs. Thus these areas require further systemic consideration and research so as to bring out commercially and valuable available niosomal preparation. The concept of incorporating the drug into or niosomes for a better targeting of the drug at appropriate tissue destination is widely accepted by researchers and academicians. The ionic drug carriers are relatively toxic and unsuitable whereas niosomal carriers are safer. And also handling and storage of niosomes require no special conditions. Niosomes represent a promising drug delivery module. They have similar structure to liposome, to little same in property and hence they can represent alternative vesicular systems with respect to liposomes, due to the niosome ability to encapsulate different type of drugs within their multienvironmental structure. Niosomes are thoughts to be better candidate drug delivery as compared to liposomes due to various factors like cost, stability etc. Niosomes have very important and key role in various types of drug deliveries; like targeting, topical, ophthalmic and parenteral. Niosomes are very useful in bright future for pharma industries. So far only animal experimentation of this targeted drug delivery system is reported but further clinical investigations in human volunteers, pharmacological and toxicological investigations in animals and human volunteers may help to exploit niosomes as prosperous drug carriers for targeting drugs more efficiently, for treating cancer, infection and AIDS etc.
